- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04785989
Profilage métabolique in vivo de la LLC (leucémie lymphoïde chronique)
Profilage métabolique des cellules leucémiques par traçage isotopique chez les patients atteints de LLC
Metabolic reprogramming has been identified as a hallmark of cancer. Almost a century after Otto Warburg initially discovered increased glycolytic activity in tumor tissue ("Warburg effect"), therapeutic targeting of cancer metabolism has become a field of intense research effort in cancer biology.
A growing appreciation of metabolic heterogeneity and complexity is currently reshaping investigators "simplistic" understanding of metabolic reprogramming in cancer. Discovering metabolic vulnerabilities as new treatment targets for cancer requires systematic dissection of metabolic dependencies, fuel preferences, and underlying mechanisms in the specific physiological context. However, today's data on cancer cell metabolic signatures and heterogeneity in their physiological habitat of the human organism is sparse to non-existent representing a critical knowledge gap in designing effective metabolic therapies. Here, the investigators propose a "top-down" approach studying cancer cell metabolism in patients followed by mechanistic in-depth studies in cell culture and animal models to define metabolic vulnerabilities.
Investigators will develop a metabolic tracing method to quantitatively characterize metabolic signatures and fuel preferences of leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL). Isotopic metabolic tracers are nutrients that are chemically identical to the native nutrient. Incorporated stable, non-radioactive isotopes allow investigators to follow their metabolic fate by monitoring conversion of tracer nutrients into downstream metabolites using cutting-edge metabolomics analysis. Using this method, investigators propose to test the hypothesis that leukemic lymphocytes show tissue-specific metabolic preferences that differ from non-leukemic lymphocytes and that ex vivo in-plasma labeling represents a useful model for assaying metabolic activity in leukemic cells in a patient-specific manner.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Cancer Connect
- Numéro de téléphone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
Lieux d'étude
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53705
- Recrutement
- University of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
To meet the study aims sixteen (16) adult participants will be enrolled: four (4) healthy volunteers defined as people without a history of cancer, 8 patients with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0, and 4 patients with high disease burden CLL defined as having extensive infiltration of the bone marrow.
La description
Inclusion Criteria:
Group A
- Adult (18 years of age or older)
- No previous history of cancer
- Routine history of normal blood counts and vital signs
- Documented Informed Consent
Group B
- Adult (18 years of age or older)
- Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.)
- Treatment naïve
- Documented Informed Consent
Group C
- Adult (18 years of age or older)
- Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia
- Treatment naïve
- Able/willing to have bone marrow aspiration
- Documented Informed Consent
Exclusion Criteria:
For all participants
- Prisoners
- Psychiatric inpatients or people who are institutionalized
- Minor (Less than 18 years of age)
- History of diabetes
- Cannot be on antihyperglycemic therapy
- Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc.
- Females of child bearing potential
- Persons without decision-making capacity
- Person who cannot read/write English
- Not meeting inclusion criteria defined above
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_CONTROL
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Group A: Healthy volunteers
Healthy volunteers are defined as people without a history of cancer |
[U-13C]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia. |
|
Group B subset-1: Treatment naïve CLL(Chronic Lymphocytic Leukemia) patients with low disease burden
Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0. |
6mg/kg of body weight of [13C5]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia. |
|
Group B subset-2: Treatment naïve CLL patients with low disease burden
Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0. |
[U-13C]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia. |
|
Group C:Treatment naïve CLL patients with high systemic disease burden
Treatment naïve CLL patients with high systemic disease burden |
[U-13C]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Amount of [U-13C]glucose incorporation into metabolites in normal and leukemic lymphocytes: Liquid chromatography-mass spectrometry (LCMS) pharmacokinetic analysis
Délai: up to 2 hours (± 5 minutes)
|
It will reveal how CLL cells utilize glucose compared to non-leukemic lymphocytes and how this changes with different disease burden and site of disease. Participants will be on overnight fasting. |
up to 2 hours (± 5 minutes)
|
|
Amount of [U-13C15N]L-glutamine incorporation into metabolites in normal and leukemic lymphocytes: LCMS pharmacokinetic analysis
Délai: up to 2 hours (± 5 minutes)
|
It will reveal how CLL cells utilize glutamine compared to non-leukemic lymphocytes and how this changes with different disease burden and site of disease. Participants will be on overnight fasting. |
up to 2 hours (± 5 minutes)
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Validate ex vivo labeling model to assay metabolism
Délai: 10 minutes
|
Study team seek to develop a more cost-effective ex vivo model to assay metabolism under conditions closest to the physiological setting in a small amount of blood. In addition, this model will allow numerous pharmacologic interventions and may serve as a personalized ex vivo drug screening assay. Participants will be on overnight fasting. Cells and plasma will be separated from 5 ml of pre infused blood. Cell suspensions will be incubated at 37°C for 2hrs and intracellular and extracellular metabolites will be extracted separately for LCMS analysis. |
10 minutes
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Christopher Fletcher, MD, School of Medicine and Public Health, University of Wisconsin, Madison
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Maladie chronique
- Attributs de la maladie
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Leucémie, cellule B
- Leucémie, Lymphoïde
- Leucémie
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Leucémie lymphocytaire chronique à cellules B
Autres numéros d'identification d'étude
- UW20062
- A534260 (Autre identifiant: UW Madison)
- SMPH/MEDICINE/HEM-ONC (Autre identifiant: UW Madison)
- MSN240796 (Autre subvention/numéro de financement: WISCONSIN ALUMNI RESEARCH FOUNDATION)
- 2020-1008 (Autre identifiant: HSIRB UW Madison)
- Protocol Version 10/19/2022 (Autre identifiant: UW Madison)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .